CL2012003643A1 - Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension. - Google Patents

Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.

Info

Publication number: CL2012003643A1
Authority: CL; Chile
Prior art keywords: compound; dyslipidemia; glucagon; hypertension; treat
Prior art date: 2010-06-23

Application number

CL2012003643A

Other languages

English (en)

Inventor

Marie Skovgaard

Ditte Riber

Eddi Meier

Jens Rosengren Daugaard

Original Assignee

Zealand Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-23

Filing date

2012-12-21

Publication date

2013-08-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44630045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003643(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-12-21 Application filed by Zealand Pharma As filed Critical Zealand Pharma As

2013-08-02 Publication of CL2012003643A1 publication Critical patent/CL2012003643A1/es

Links

150000001875 compounds Chemical class 0.000 title 3
208000032928 Dyslipidaemia Diseases 0.000 title 1
102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
206010020772 Hypertension Diseases 0.000 title 1
208000017170 Lipid metabolism disease Diseases 0.000 title 1
208000008589 Obesity Diseases 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1
235000020824 obesity Nutrition 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2012003643A 2010-06-23 2012-12-21 Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension. CL2012003643A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA201000550		2010-06-23
US35862310P	2010-06-25	2010-06-25

Publications (1)

Publication Number	Publication Date
CL2012003643A1 true CL2012003643A1 (es)	2013-08-02

Family

ID=44630045

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012003643A CL2012003643A1 (es)	2010-06-23	2012-12-21	Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.

Country Status (23)

Country	Link
US (2)	US9403894B2 (es)
EP (1)	EP2585481B1 (es)
JP (1)	JP5937582B2 (es)
KR (1)	KR20130086339A (es)
CN (1)	CN103038250A (es)
AP (1)	AP3286A (es)
AR (1)	AR081975A1 (es)
AU (1)	AU2011269427A1 (es)
BR (1)	BR112012033227A2 (es)
CA (1)	CA2802889A1 (es)
CL (1)	CL2012003643A1 (es)
CO (1)	CO6660484A2 (es)
EA (1)	EA201291233A1 (es)
EC (1)	ECSP12012351A (es)
MX (1)	MX2012014774A (es)
NZ (1)	NZ604033A (es)
PE (1)	PE20130326A1 (es)
PH (1)	PH12012502461A1 (es)
SG (1)	SG186276A1 (es)
TN (1)	TN2012000567A1 (es)
TW (1)	TW201202265A (es)
UY (1)	UY33462A (es)
WO (1)	WO2011160630A2 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1877435T2 (sl)	2005-05-04	2021-05-31	Zealand Pharma A/S	Analogi glukagonu podobnega peptida-2(GLP-2)
EP2051995B1 (en)	2006-11-08	2017-02-08	Zealand Pharma A/S	Selective glucagon-like-peptide-2 (glp-2) analogues
WO2010070252A1 (en)	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
NZ593813A (en)	2008-12-15	2013-02-22	Zealand Pharma As	Glucagon analogues
JP5635529B2 (ja)	2008-12-15	2014-12-03	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
JP5635531B2 (ja)	2008-12-15	2014-12-03	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
ME02220B (me)	2009-07-13	2016-02-20	Zealand Pharma As	Analozi acilovanog glukagona
AR081975A1 (es)	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
EP2585482B1 (en)	2010-06-24	2019-03-27	Zealand Pharma A/S	Glucagon analogues
MA34913B1 (fr) *	2011-01-20	2014-02-01	Zealand Pharma As	Combinaison d'analogues du glucagon acylé à des analogues d'insuline
JP6352806B2 (ja)	2011-09-23	2018-07-04	ノヴォノルディスクアー／エス	新規のグルカゴン類似体
SG11201403377QA (en) *	2011-12-23	2014-07-30	Zealand Pharma As	Glucagon analogues
KR20150006052A (ko) *	2012-05-03	2015-01-15	질랜드 파마 에이/에스	글루카곤-유사 펩타이드-2 (ｇｌｐ-2) 유사체
WO2013164483A1 (en)	2012-05-03	2013-11-07	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
AR091422A1 (es)	2012-06-14	2015-02-04	Sanofi Sa	Analogos peptidicos de la exendina 4
MY170671A (en)	2012-07-23	2019-08-26	Zealand Pharma As	Glucagon analogues
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
EP2895506A1 (en)	2012-09-17	2015-07-22	Imperial Innovations Limited	Peptide analogues of glucagon and glp1
GB2505941A (en) *	2012-09-17	2014-03-19	Imp Innovations Ltd	Peptide analogues of glucagon for the treatment of obesity and diabetes
UA116217C2 (uk) *	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en)	2012-12-21	2017-07-28	Sanofi Sa	Functionalized exendin-4 derivatives
ES2623979T3 (es)	2013-03-21	2017-07-12	Sanofi-Aventis Deutschland Gmbh	Síntesis de productos peptídicos que contienen hidantoína
ES2624961T3 (es)	2013-03-21	2017-07-18	Sanofi-Aventis Deutschland Gmbh	Síntesis de productos de péptido que contienen imida cíclica
AR095986A1 (es)	2013-04-03	2015-11-25	Sanofi Sa	Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
PL2986313T3 (pl)	2013-04-18	2019-12-31	Novo Nordisk A/S	Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
SI3057984T1 (sl)	2013-10-17	2018-10-30	Zealand Pharma A/S	Acilirani glukagonski analogi
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
US10093713B2 (en)	2013-11-06	2018-10-09	Zealand Pharma A/S	GIP-GLP-1 dual agonist compounds and methods
EA035688B1 (ru)	2013-11-06	2020-07-27	Зилэнд Фарма А/С	Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
EP3080149A1 (en)	2013-12-13	2016-10-19	Sanofi	Dual glp-1/glucagon receptor agonists
WO2015086731A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
WO2015086729A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/gip receptor agonists
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
EP3151852A1 (en)	2014-06-04	2017-04-12	Novo Nordisk A/S	Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
TWI705973B (zh)	2014-10-29	2020-10-01	丹麥商西蘭製藥公司	Ｇｉｐ促效劑化合物及方法
MA52253A (fr)	2015-02-17	2021-02-17	Lilly Co Eli	Formulation de poudre nasale pour le traitement de l'hypoglycémie
CN107567459B (zh)	2015-03-18	2021-09-24	西兰制药公司	胰淀素类似物
WO2016168388A2 (en)	2015-04-14	2016-10-20	Palatin Technologies, Inc.	Therapies for obesity, diabetes and related indications
TWI707867B (zh)	2015-04-16	2020-10-21	丹麥商西蘭製藥公司	醯化之昇糖素類似物
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en)	2015-06-12	2016-12-15	Sanofi	Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
EP3888667B1 (en)	2016-06-09	2023-10-25	AmideBio LLC	Glucagon analog and methods of use thereof
JP6651054B2 (ja)	2016-08-05	2020-02-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グレリンｏ−アシルトランスフェラーゼ（ｇｏａｔ）阻害薬として使用するためのオキサジアゾロピリジン誘導体
TWI784968B (zh)	2016-09-09	2022-12-01	丹麥商西蘭製藥公司	澱粉素類似物
KR101887577B1 (ko) *	2016-10-19	2018-09-10	(주)케어젠	항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
AR110299A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
WO2018104561A1 (en)	2016-12-09	2018-06-14	Zealand Pharma A/S	Acylated glp-1/glp-2 dual agonists
DK3881861T3 (da)	2017-06-16	2024-09-09	Zealand Pharma As	Doseringsregimer for indgivelse af glukagonlignende peptid-2- (GLP-2)-analoger
HUE065912T2 (hu) *	2017-08-16	2024-06-28	Dong A St Co Ltd	Acilezett oxintomodulin peptid analóg
JP7083397B2 (ja)	2018-02-02	2022-06-10	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのトリアゾロピリミジン誘導体
WO2019149658A1 (en)	2018-02-02	2019-08-08	Boehringer Ingelheim International Gmbh	Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
CA3087826A1 (en)	2018-02-02	2019-08-08	Boehringer Ingelheim International Gmbh	Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
CR20200331A (es)	2018-02-02	2020-09-03	Boehringer Ingelheim Int	Derivados de oxadiazolopirisdina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltrasferasa (goat)
BR112020020647A2 (pt)	2018-04-10	2021-02-23	Sanofi-Aventis Deutschland Gmbh	síntese de lixisenatida com capeamento
KR102793451B1 (ko) *	2018-04-10	2025-04-11	사노피-아벤티스 도이칠란트 게엠베하	고체상으로부터 고체상-결합된 펩타이드를 절단하는 방법
BR112021011595A2 (pt)	2018-12-21	2021-11-30	Jiangsu Hengrui Medicine Co	Proteína biespecífica
TWI771669B (zh)	2019-04-26	2022-07-21	美商美國禮來大藥廠	製備穩定胜肽調配物之方法
CN115380043A (zh) *	2019-08-13	2022-11-22	安医健有限公司	艾塞那肽类似物及其用途
PE20221168A1 (es)	2019-11-11	2022-07-25	Boehringer Ingelheim Int	Agonistas del receptor npy2
PL4153600T3 (pl)	2020-05-22	2024-12-16	Boehringer Ingelheim International Gmbh	Sposób ciągły wytwarzania 7-amino-5-metylo-[1,2,5]oksadiazolo[3,4- b]pirydynokarboksylanu alkilu
WO2021233882A1 (en)	2020-05-22	2021-11-25	Boehringer Ingelheim International Gmbh	Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
CN113292646B (zh) *	2020-05-29	2022-05-13	东莞云璟生物技术有限公司	Glp-1/胰高血糖素双重激动剂融合蛋白
UA130066C2 (uk)	2020-08-07	2025-10-29	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Розчинні агоністи рецепторів npy2
WO2024165571A2 (en)	2023-02-06	2024-08-15	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025125576A2 (en)	2023-12-15	2025-06-19	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025133348A1 (en)	2023-12-22	2025-06-26	E-Therapeutics Plc	Inhibitors of expression and/or function
EP4686757A1 (en)	2024-07-31	2026-02-04	e-therapeutics PLC	Inhibitors of expression and/or function
WO2025196502A1 (en)	2024-03-20	2025-09-25	North Carolina Agricultural & Technical State University	Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ202757A (en)	1981-12-23	1985-11-08	Novo Industri As	Peptides and medicaments
IL128332A0 (en)	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
NZ334595A (en)	1996-09-09	2000-08-25	Zealand Pharmaceuticals As	Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage
CZ295838B6 (cs)	1996-09-09	2005-11-16	Zealand Pharma A/S	Způsob výroby peptidů
WO1999025727A2 (en)	1997-11-14	1999-05-27	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
JP4394279B2 (ja)	1998-03-09	2010-01-06	ジーランドファーマアクティーゼルスカブ	酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
CN1495198A (zh)	1998-12-07	2004-05-12	�о��Ӧ�ÿ�ѧЭ��ɷ��޹�˾	胰高血糖素样肽-1的类似物
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
PL351326A1 (en)	1999-03-17	2003-04-07	Novo Nordisk As	Method for acylating peptides and novel acylating agents
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
AU2002346491A1 (en)	2001-12-19	2003-07-09	Eli Lilly And Company	Crystalline compositions for controlling blood glucose
BR0215029A (pt)	2001-12-20	2005-12-20	Lilly Co Eli	Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
US20060217290A1 (en)	2003-04-29	2006-09-28	Kohn Wayne D	Insulin analogs having protracted time action
DK1891105T3 (da)	2005-06-13	2012-07-16	Imp Innovations Ltd	Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd
WO2007024899A2 (en)	2005-08-23	2007-03-01	The General Hospital Corporation	Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
US8338368B2 (en)	2005-11-07	2012-12-25	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
US8343914B2 (en)	2006-01-06	2013-01-01	Case Western Reserve University	Fibrillation resistant proteins
WO2007100535A2 (en)	2006-02-22	2007-09-07	Merck & Co., Inc.	Oxyntomodulin derivatives
NZ574215A (en)	2006-07-18	2012-07-27	Sanofi Aventis	Antagonist antibody against epha2 for the treatment of cancer
ES2554773T3 (es)	2006-10-04	2015-12-23	Case Western Reserve University	Insulina y análogos de la insulina resistentes a la fibrilación
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
JP6017754B2 (ja)	2007-02-15	2016-11-02	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルカゴン／ｇｌｐ−１受容体コアゴニスト
DK2158214T3 (da)	2007-06-15	2011-12-05	Zealand Pharma As	Glukagonanaloger
EP2025684A1 (en)	2007-08-15	2009-02-18	Zealand Pharma A/S	Glucagon analogues
US8946148B2 (en)	2007-11-20	2015-02-03	Ambrx, Inc.	Modified insulin polypeptides and their uses
PL2229407T3 (pl)	2008-01-09	2017-06-30	Sanofi-Aventis Deutschland Gmbh	Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
DE102008003566A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
NZ586589A (en)	2008-01-09	2012-04-27	Sanofi Aventis Deutschland	Novel insulin analogues having an extremely delayed time-action profile
DE102008003568A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
US8993516B2 (en)	2008-04-14	2015-03-31	Case Western Reserve University	Meal-time insulin analogues of enhanced stability
CN102065885A (zh)	2008-04-22	2011-05-18	卡斯西部储备大学	同种型特异性的胰岛素类似物
TWI451876B (zh)	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
AU2009260302B2 (en)	2008-06-17	2014-10-23	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
JP5753779B2 (ja)	2008-06-17	2015-07-22	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
PL219335B1 (pl)	2008-07-04	2015-04-30	Inst Biotechnologii I Antybiotyków	Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
KR20110061552A (ko)	2008-07-31	2011-06-09	케이스 웨스턴 리저브 유니버시티	할로겐 안정화된 인슐린
JP5635529B2 (ja)	2008-12-15	2014-12-03	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
JP5635531B2 (ja)	2008-12-15	2014-12-03	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
NZ593813A (en) *	2008-12-15	2013-02-22	Zealand Pharma As	Glucagon analogues
WO2010070252A1 (en)	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
WO2010080606A1 (en)	2008-12-19	2010-07-15	Indiana University Research And Technology Corporation	Insulin analogs
CN102245624B (zh)	2008-12-19	2016-08-10	印第安纳大学研究及科技有限公司	基于酰胺的胰岛素前药
CN101519446A (zh)	2009-03-31	2009-09-02	上海一就生物医药有限公司	一种重组人胰岛素及其类似物的制备方法
ME02220B (me)	2009-07-13	2016-02-20	Zealand Pharma As	Analozi acilovanog glukagona
JP2013517307A (ja) *	2010-01-20	2013-05-16	ジーランドファーマアクティーゼルスカブ	心臓病の処置
AR081975A1 (es)	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
EP2585482B1 (en)	2010-06-24	2019-03-27	Zealand Pharma A/S	Glucagon analogues
MA34913B1 (fr)	2011-01-20	2014-02-01	Zealand Pharma As	Combinaison d'analogues du glucagon acylé à des analogues d'insuline
SG11201403377QA (en)	2011-12-23	2014-07-30	Zealand Pharma As	Glucagon analogues
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
SI3057984T1 (sl)	2013-10-17	2018-10-30	Zealand Pharma A/S	Acilirani glukagonski analogi

2011
- 2011-06-22 AR ARP110102166A patent/AR081975A1/es unknown
- 2011-06-22 UY UY0001033462A patent/UY33462A/es not_active Application Discontinuation
- 2011-06-23 AU AU2011269427A patent/AU2011269427A1/en not_active Abandoned
- 2011-06-23 MX MX2012014774A patent/MX2012014774A/es not_active Application Discontinuation
- 2011-06-23 AP AP2013006669A patent/AP3286A/xx active
- 2011-06-23 PE PE2012002434A patent/PE20130326A1/es not_active Application Discontinuation
- 2011-06-23 BR BR112012033227A patent/BR112012033227A2/pt not_active IP Right Cessation
- 2011-06-23 EP EP11741513.3A patent/EP2585481B1/en active Active
- 2011-06-23 CA CA2802889A patent/CA2802889A1/en not_active Abandoned
- 2011-06-23 WO PCT/DK2011/000067 patent/WO2011160630A2/en not_active Ceased
- 2011-06-23 SG SG2012090890A patent/SG186276A1/en unknown
- 2011-06-23 TW TW100122081A patent/TW201202265A/zh unknown
- 2011-06-23 NZ NZ604033A patent/NZ604033A/en not_active IP Right Cessation
- 2011-06-23 EA EA201291233A patent/EA201291233A1/ru unknown
- 2011-06-23 US US13/702,841 patent/US9403894B2/en not_active Expired - Fee Related
- 2011-06-23 CN CN2011800305150A patent/CN103038250A/zh active Pending
- 2011-06-23 JP JP2013515697A patent/JP5937582B2/ja not_active Expired - Fee Related
- 2011-06-23 KR KR1020137000529A patent/KR20130086339A/ko not_active Withdrawn
- 2011-06-23 PH PH1/2012/502461A patent/PH12012502461A1/en unknown
2012
- 2012-11-30 TN TNP2012000567A patent/TN2012000567A1/en unknown
- 2012-12-20 EC ECSP12012351 patent/ECSP12012351A/es unknown
- 2012-12-21 CO CO12232550A patent/CO6660484A2/es unknown
- 2012-12-21 CL CL2012003643A patent/CL2012003643A1/es unknown
2016
- 2016-06-27 US US15/194,025 patent/US20160304576A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US9403894B2 (en)	2016-08-02
SG186276A1 (en)	2013-01-30
AP3286A (en)	2015-05-31
MX2012014774A (es)	2013-01-29
EA201291233A1 (ru)	2013-07-30
KR20130086339A (ko)	2013-08-01
CA2802889A1 (en)	2011-12-29
EP2585481A2 (en)	2013-05-01
US20160304576A1 (en)	2016-10-20
AP2013006669A0 (en)	2013-01-31
BR112012033227A2 (pt)	2017-06-20
WO2011160630A2 (en)	2011-12-29
JP5937582B2 (ja)	2016-06-22
UY33462A (es)	2012-01-31
TW201202265A (en)	2012-01-16
PH12012502461A1 (en)	2013-02-18
PE20130326A1 (es)	2013-03-17
EP2585481B1 (en)	2015-08-19
CO6660484A2 (es)	2013-04-30
US20130157935A1 (en)	2013-06-20
JP2013534919A (ja)	2013-09-09
AU2011269427A1 (en)	2012-12-20
WO2011160630A3 (en)	2012-02-16
CN103038250A (zh)	2013-04-10
NZ604033A (en)	2014-12-24
ECSP12012351A (es)	2013-01-31
AR081975A1 (es)	2012-10-31
TN2012000567A1 (en)	2014-04-01

Publication	Publication Date	Title
CL2012003643A1 (es)	2013-08-02	Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2011001299A1 (es)	2012-01-13	Compuestos derivados de benzotiazoles; composicion farmaceutica; y su uso como inhibidores de raf para el tratamiento o profilaxis del cancer.
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
CL2011002877A1 (es)	2012-05-25	Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2012003415A1 (es)	2013-08-09	Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2015001207A1 (es)	2015-07-03	Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas, que comprende un análogo de oxintomodulina; y uso de la composición.
CL2014000801A1 (es)	2014-09-12	Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos.
CL2013001338A1 (es)	2014-03-28	Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2012002606A1 (es)	2013-10-18	Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
CL2013003372A1 (es)	2014-07-25	Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2014001858A1 (es)	2014-09-26	Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CL2012000772A1 (es)	2012-08-24	Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2013000801A1 (es)	2013-11-29	Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
GT201400147A (es)	2015-04-06	Pirimidinas y triazinas fusionadas sustituidas y su uso
BR112012016398A2 (pt)	2018-08-21	Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
CO6440531A2 (es)	2012-05-15	2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CL2008000793A1 (es)	2008-05-30	Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.
CL2014002348A1 (es)	2015-01-23	Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
CL2014003339A1 (es)	2015-04-10	Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor.
CL2014003525A1 (es)	2015-04-10	Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
CL2012003322A1 (es)	2014-03-28	Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
CL2015001202A1 (es)	2015-07-03	Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2013001324A1 (es)	2014-05-16	Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer.
CL2014001861A1 (es)	2014-11-07	Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.